CU20170123A7 - Heterociclilmetil-tienouracilo como antagonistas del receptor de adenosina-a2b - Google Patents

Heterociclilmetil-tienouracilo como antagonistas del receptor de adenosina-a2b

Info

Publication number
CU20170123A7
CU20170123A7 CUP2017000123A CU20170123A CU20170123A7 CU 20170123 A7 CU20170123 A7 CU 20170123A7 CU P2017000123 A CUP2017000123 A CU P2017000123A CU 20170123 A CU20170123 A CU 20170123A CU 20170123 A7 CU20170123 A7 CU 20170123A7
Authority
CU
Cuba
Prior art keywords
adenosine receptor
tienouracilo
heterociclilmetil
antagonists
tienouracil
Prior art date
Application number
CUP2017000123A
Other languages
English (en)
Inventor
Martina Delbeck
Michael Haerter
Bernd Kalthof
Dirk Kosemund
Klemens Lustig
Frank Suessmeier
Pierre Wasnaire
Original Assignee
Bayer Pharma AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bayer Pharma AG filed Critical Bayer Pharma AG
Publication of CU20170123A7 publication Critical patent/CU20170123A7/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/10—Antioedematous agents; Diuretics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Cardiology (AREA)
  • Epidemiology (AREA)
  • Pulmonology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Transplantation (AREA)
  • Hospice & Palliative Care (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

<p>La presente solicitud se refiere a derivados novedosos de tieno[2,3-d]pirimidina-2,4-diona(¨tienouracilo¨) como agonistas del recpetor de adenosina A2b</p> <p>ESPACIO PARA LA FÓRMULA</p> <p>que presentan un tipo particular de sustituyente (azaheterociclil)metilo, y a procesos para la preparación de los mismos, y a medicamentos que contiene a los mismos por sí solos o en combinaciones.</p>
CUP2017000123A 2015-03-26 2016-03-21 Heterociclilmetil-tienouracilo como antagonistas del receptor de adenosina-a2b CU20170123A7 (es)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
EP15161165 2015-03-26
EP15174566 2015-06-30
EP15184732 2015-09-10
PCT/EP2016/056106 WO2016150901A1 (de) 2015-03-26 2016-03-21 Heterocyclylmethyl-thienouracile als antagonisten des adenosin-a2b-rezeptors

Publications (1)

Publication Number Publication Date
CU20170123A7 true CU20170123A7 (es) 2018-02-08

Family

ID=55586319

Family Applications (1)

Application Number Title Priority Date Filing Date
CUP2017000123A CU20170123A7 (es) 2015-03-26 2016-03-21 Heterociclilmetil-tienouracilo como antagonistas del receptor de adenosina-a2b

Country Status (24)

Country Link
US (1) US10428083B2 (es)
EP (1) EP3274352B1 (es)
JP (1) JP2018509443A (es)
KR (1) KR20170131540A (es)
CN (1) CN107646035A (es)
AU (1) AU2016236272A1 (es)
BR (1) BR112017020317A2 (es)
CA (1) CA2980646A1 (es)
CL (1) CL2017002390A1 (es)
CO (1) CO2017009656A2 (es)
CR (1) CR20170437A (es)
CU (1) CU20170123A7 (es)
DO (1) DOP2017000212A (es)
EA (1) EA201792134A1 (es)
EC (1) ECSP17064196A (es)
IL (1) IL254476A0 (es)
MX (1) MX2017012308A (es)
PE (1) PE20180116A1 (es)
PH (1) PH12017501758A1 (es)
SG (1) SG11201707577VA (es)
TN (1) TN2017000415A1 (es)
TW (1) TW201700480A (es)
UY (1) UY36586A (es)
WO (1) WO2016150901A1 (es)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2018041771A1 (de) 2016-09-02 2018-03-08 Bayer Pharma Aktiengesellschaft (1-methylcyclopropyl)methyl-substituierte thienouracile und ihre verwendung
EP3515919A1 (de) 2016-09-23 2019-07-31 Bayer Aktiengesellschaft N3-cyclisch substituierte thienouracile und ihre verwendung
JP6999112B2 (ja) * 2016-11-29 2022-02-04 国立研究開発法人産業技術総合研究所 ２，５－ビス（アミノメチル）フラン二ハロゲン化水素塩及びその製造方法並びに２，５－ビス（アミノメチル）フランの製造方法
CN112955441B (zh) 2018-10-24 2024-06-18 里德埃克斯普洛股份公司 官能化氨基三嗪
CN113727999A (zh) 2019-01-11 2021-11-30 奥默罗斯公司 用于治疗癌症的方法和组合物
WO2020172338A1 (en) * 2019-02-19 2020-08-27 Whitehead Institute For Biomedical Research Methods and agents for modulating mitochondrial nad levels
CN112608330B (zh) 2019-07-30 2021-09-28 杭州阿诺生物医药科技有限公司 A2a和/或a2b受体抑制剂
CN112479956A (zh) 2019-07-30 2021-03-12 杭州阿诺生物医药科技有限公司 一种用于制备腺苷受体抑制剂中间体的方法
WO2021252951A1 (en) 2020-06-12 2021-12-16 Vanderbilt University Methods of treatment for gastrointestinal motility disorders
CN111875615A (zh) * 2020-07-15 2020-11-03 济南大学 一种甲氧基苄脲类化合物及其用途
CA3192236A1 (en) 2020-09-10 2022-03-17 Tony Lahoutte Antibody fragment against fap
WO2023203135A1 (en) 2022-04-22 2023-10-26 Precirix N.V. Improved radiolabelled antibody
AU2023264245A1 (en) 2022-05-02 2024-12-19 Precirix N.V. Pre-targeting

Family Cites Families (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2036171A1 (es) 1970-07-21 1972-01-27
US6140325A (en) 1993-08-19 2000-10-31 Takeda Chemical Industries, Ltd. Thienopyrimidine derivatives, their production and use
TW276256B (es) * 1993-08-26 1996-05-21 Takeda Pharm Industry Co Ltd
WO2000061583A1 (en) 1995-06-07 2000-10-19 Cell Therapeutics, Inc. Xanthine derivatives and analogs as cell signaling inhibitors
JP3728324B2 (ja) 1997-02-26 2005-12-21 北興化学工業株式会社 １−置換−４−カルバモイル−１，２，４−トリアゾール−５−オン誘導体及び除草剤
SE9702001D0 (sv) 1997-05-28 1997-05-28 Astra Pharma Prod Novel compounds
DE19834047A1 (de) 1998-07-29 2000-02-03 Bayer Ag Substituierte Pyrazolderivate
DE19834044A1 (de) 1998-07-29 2000-02-03 Bayer Ag Neue substituierte Pyrazolderivate
CA2339664A1 (en) 1998-08-28 2000-03-09 Astrazeneca Ab Thieno{2,3,-d}pyrimidinedione derivatives and their use as immunosuppressants
DE19943634A1 (de) 1999-09-13 2001-04-12 Bayer Ag Neuartige Dicarbonsäurederivate mit pharmazeutischen Eigenschaften
DE19943639A1 (de) 1999-09-13 2001-03-15 Bayer Ag Dicarbonsäurederivate mit neuartigen pharmazeutischen Eigenschaften
DE19943635A1 (de) 1999-09-13 2001-03-15 Bayer Ag Neuartige Aminodicarbonsäurederivate mit pharmazeutischen Eigenschaften
DE19943636A1 (de) 1999-09-13 2001-03-15 Bayer Ag Neuartige Dicarbonsäurederivate mit pharmazeutischen Eigenschaften
ATE272642T1 (de) * 2000-05-04 2004-08-15 Astrazeneca Ab Thieno(2,3-d)pyrimidindione und ihre verwendung als pharmazeutische mittel
GB2363377B (en) * 2000-06-14 2004-06-09 Astrazeneca Ab Novel thieno[2,3-d]pyrimidinediones and therapeutic uses thereof
AR031176A1 (es) 2000-11-22 2003-09-10 Bayer Ag Nuevos derivados de pirazolpiridina sustituidos con piridina
WO2002064598A1 (en) 2001-02-14 2002-08-22 Warner-Lambert Company Llc Thieno'2,3-d pyrimidindione derivatives as matrix metalloproteinase inhibitors
DE10110750A1 (de) 2001-03-07 2002-09-12 Bayer Ag Neuartige Aminodicarbonsäurederivate mit pharmazeutischen Eigenschaften
DE10110749A1 (de) 2001-03-07 2002-09-12 Bayer Ag Substituierte Aminodicarbonsäurederivate
DE10220570A1 (de) 2002-05-08 2003-11-20 Bayer Ag Carbamat-substituierte Pyrazolopyridine
AU2003253165A1 (en) 2002-08-13 2004-02-25 Warner-Lambert Company Llc Pyrimidine fused bicyclic metalloproteinase inhibitors
US6890923B2 (en) * 2002-12-16 2005-05-10 Astrazeneca Ab Compounds
WO2004065395A1 (en) * 2003-01-17 2004-08-05 Astrazeneca Ab Thienopyridazinones and their use in modulation of autoimmune disease
SE0300119D0 (sv) * 2003-01-17 2003-01-17 Astrazeneca Ab Novel compounds
AU2005282523A1 (en) 2004-09-02 2006-03-16 3M Innovative Properties Company 2-amino 1H imidazo ring systems and methods
JP2009528389A (ja) * 2006-03-02 2009-08-06 シーブイ・セラピューティクス・インコーポレイテッド Ａ２ａアデノシン受容体拮抗剤
CA2670788A1 (en) 2006-12-01 2008-06-12 Cv Therapeutics, Inc. A2a adenosine receptor antagonists
GB0718432D0 (en) * 2007-09-21 2007-10-31 Vernalis R&D Ltd New chemical compounds
WO2010089580A1 (en) * 2009-02-06 2010-08-12 Astrazeneca Ab Use of a mct1 inhibitor in the treatment of cancers expressing mct1 over mct4
DE102010021637A1 (de) 2010-05-26 2011-12-01 Bayer Schering Pharma Aktiengesellschaft Substituierte 5-Fluor-1H-Pyrazolopyridine und ihre Verwendung
CA2804470A1 (en) 2010-07-09 2012-01-12 Bayer Intellectual Property Gmbh Ring-fused pyrimidines and triazines and use thereof for the treatment and/or prophylaxis of cardiovascular diseases
DE102010040233A1 (de) 2010-09-03 2012-03-08 Bayer Schering Pharma Aktiengesellschaft Bicyclische Aza-Heterocyclen und ihre Verwendung
BR112013006344A2 (pt) 2010-09-17 2016-06-21 Array Biopharma Inc lactamas substituídas por piperdinila como moduladores de gpr119, composição farmacêutica as compreendendo, uso e processso para preparação das mesmas
DE102010043379A1 (de) 2010-11-04 2012-05-10 Bayer Schering Pharma Aktiengesellschaft Substituierte 6-Fluor-1H-Pyrazolo[4,3-b]pyridine und ihre Verwendung
WO2012166700A2 (en) * 2011-05-29 2012-12-06 Lisanti Michael P Molecular profiling of a lethal tumor microenvironment
ES2665580T3 (es) 2011-11-11 2018-04-26 Gilead Apollo, Llc Inhibidores de ACC y usos de los mismos
US10085987B2 (en) * 2012-01-27 2018-10-02 Thomas Jefferson University MCT protein inhibitor-related prognostic and therapeutic methods
US20130287791A1 (en) * 2012-04-25 2013-10-31 C. Wilson Xu Modulation of histone h2b monoubiquitination and treatment of cancer
CA2911818A1 (en) 2013-05-10 2014-11-13 Nimbus Apollo, Inc. Acc inhibitors and uses thereof
MX2015015417A (es) 2013-05-10 2016-06-21 Nimbus Apollo Inc Inhibidores de acetil-coa carboxilasa (acc) y usos de los mismos.
AP2016009128A0 (en) * 2013-10-07 2016-04-30 Bayer Pharma AG Cyclic thienouracil-carboxamides and use thereof

Also Published As

Publication number Publication date
EA201792134A1 (ru) 2018-03-30
DOP2017000212A (es) 2017-11-15
ECSP17064196A (es) 2017-10-31
UY36586A (es) 2016-10-31
TN2017000415A1 (en) 2019-01-16
PE20180116A1 (es) 2018-01-18
JP2018509443A (ja) 2018-04-05
US20180065981A1 (en) 2018-03-08
EP3274352A1 (de) 2018-01-31
CL2017002390A1 (es) 2018-05-11
CN107646035A (zh) 2018-01-30
PH12017501758A1 (en) 2018-04-11
CA2980646A1 (en) 2016-09-29
MX2017012308A (es) 2018-01-26
KR20170131540A (ko) 2017-11-29
AU2016236272A1 (en) 2017-10-12
BR112017020317A2 (pt) 2018-06-05
SG11201707577VA (en) 2017-10-30
EP3274352B1 (de) 2019-01-02
IL254476A0 (en) 2017-11-30
US10428083B2 (en) 2019-10-01
CR20170437A (es) 2017-11-14
CO2017009656A2 (es) 2018-01-16
WO2016150901A1 (de) 2016-09-29
TW201700480A (zh) 2017-01-01

Similar Documents

Publication Publication Date Title
CL2017002390A1 (es) Heterociclilmetil-tienouracilo como agonistas del receptor de adenosina a2b
FR22C1006I2 (fr) Derives de pyrrolo-[2,3-d]pyrimidine en tant qu&#39;inhibiteurs des janus kinases (jak)
CR20160400A (es) Derivados de nucleosido sustituidos con 4´-difluorometilo como inhibidores de la replicación de arn de la influenza
CO2017008403A2 (es) Derivados de nucleósidos sustituidos útiles como agentes antineoplásicos
CU20170160A7 (es) Derivadosde fenil-tieno(2,3-d)pirimidina- hidroxi-ésteres, un proceso para su preparación y composiciones farmacéuticas que lo contienen
NI201600144A (es) Derivados de quinoxalina utiles como moduladores del fgfr cinasa
MX2018001721A (es) 5-bromo-2,6-di-(1h-pirazol-1-il) pirimidin-4-amina-para su uso en el tratamiento del cancer.
CL2018002811A1 (es) Derivados de aminotiazol útiles como agentes antivíricos.
SI3379933T1 (sl) Fungicidni sestavki, ki vsebujejo derivate 2,4-diokso-1,4-dihidrotieno (2,3-d)pirimidina
CR20150228A (es) Inhibidores de la tirosina-quinasa de bruton
CR20150263A (es) Compuestos de pirrolopirimidina como inhibidores de quinasas
CL2015003686A1 (es) Derivados de pirrolo[3,2-d]pirimidina para el tratamiento de infecciones víricas y otras enfermedades
DOP2015000270A (es) Potenciador de inhibidores del homólogo de zeste
CO7131375A2 (es) Uracilos sustituidos bicíclicamente y uso de los mismos
MX2018007084A (es) Inhibidores de la tirosina quinasa de bruton y metodos de su uso.
EA201591939A1 (ru) ПРОИЗВОДНЫЕ ПИРРОЛО[2,3-d]ПИРИМИДИНА В КАЧЕСТВЕ АГОНИСТОВ РЕЦЕПТОРА CB2
MX2015014757A (es) Derivados de purina como agonistas del receptor de cannabinoides 2 (cb2).
CU20160044A7 (es) DERIVADOS DE 2,4 DIOXO-1,2,3,4-TETRAHIDROTIENO(2,3-d) PIRIMIDINA-6-CARBOXAMIDAS COMO ANTAGONISTAS DE RECEPTORES A2b DE ADENOSINA
EP2968331A4 (en) PYRROLOPYRIMIDINE COMPOUNDS AS KINASEINHIBITORS
LV14851A (lv) Triazolilpur&amp;imacr;na atvasin&amp;amacr;jumi k&amp;amacr; adenoz&amp;imacr;na un pur&amp;imacr;na receptoru agonisti
CL2018000349A1 (es) 5-bromo-2,6-di-(1h-pyrazol-1-il) pyrimidin-4-amina para uso en el tratamiento del cancér.